MS patients try stepping down from strong drugs in new safety trial
NCT ID NCT06529406
Summary
This study is testing if it's safe and effective for people with stable relapsing multiple sclerosis (MS) to switch from powerful infusion/injection therapies (anti-CD20 drugs) to a daily pill called ozanimod. The goal is to see if the milder pill can maintain disease control while potentially reducing risks and treatment burden. Researchers will follow 100 participants for three years, comparing them to a larger group who stay on their original therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Cleveland Clinic
RECRUITINGLas Vegas, Nevada, 89106, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Colorado Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.